Individual decision making about lung cancer screening: A conjoint analysis of perspectives among a high-risk national sample

Margaret M. Byrne1 | Richard J. Thurer2 | Jamie L. Studts3,4

Abstract

Objectives: Lung cancer screening (LCS) is effective in reducing lung cancer mortality, but there is limited information available regarding preferences among high-risk individuals concerning LCS. In this study, we use a conjoint valuation analysis (CVA) to better understand which LCS attributes most affect LCS preferences.

Materials and Methods: We implemented a web-based nationally representative survey that included a full-profile CVA exercise. Participants were over the age of 45, had at least a 20 pack-year smoking history, and no history of lung cancer. The CVA instrument included five LCS attributes, and additional survey items collected demographic and psychosocial information.

Results: Participants (n = 210) had a mean age of 61 (SD 8.5) years, approximately half were female (51.9%), and were racially/ethnically diverse. Average relative importance of the LCS program attributes was (from high to low): out of pocket costs (27.3 ± 17.7); provider recommendation (24.8 ± 13.4); mortality reduction (17.2 ± 8.9); false-positive rate (15.8 ± 10.4); and ease of access (14.8 ± 7.3). There was large variation among individuals, but few significant associations of propensity to screen with individual demographic characteristics. Average screening propensity across individuals (1‐9 scale) was 3.63 ± 1.6, and average rates of individual scenarios ranged from 2.60 ± 2.00 to 5.57 ± 2.13, indicating low inclination for screening.

Conclusions: We found that overall propensity for screening is low in a high-risk population, and that out of pocket costs were of greater importance to potential screeners than mortality reduction or false-positive rates. Thus, individuals considering or eligible for LCS need additional education and support regarding the LCS landscape in order to achieve informed decision making.

KEYWORDS
decision making, lung cancer screening, patient preferences
INTRODUCTION

Lung cancer is the leading cause of cancer mortality in the United States, with an estimated 228,150 new cases and 142,670 estimated death for 2019. In 2011, the National Lung Cancer Screening Trial reported a 20% relative reduction in lung cancer mortality with annual low-dose computed tomography (LDCT) compared to traditional chest X-ray. Subsequently, the US Preventive Services Task Force gave a Grade B recommendation for lung cancer screening (LCS) using LDCT for high-risk individuals, prompting comparable organizational guidelines. Additional data emerging from the NELSON trial similarly support the decision to disseminate LCS to high-risk individuals. All LCS recommendations emphasize informed and shared decision making.

The inclusion of shared decision-making in LCS guidelines reflects the fact that LCS generates notable potential harms as well as benefits. The principal harms include false-positive results, over-diagnosis, radiation exposure, and psychological distress, specifically for patients who receive an indeterminate or positive result. Additional harms, such as financial strain and opportunity costs, have also been noted. An understanding of the balance between the benefits and potential harms of LCS is necessary for patients to formulate preferences and make informed decisions.

The current literature for LCS demonstrates that while patient interest in LCS is generally high, preferences are influenced by a number of patient and screen-specific factors. One unique approach to LCS preference elicitation involves conjoint valuation analysis (CVA), which measures the joint effects of two or more independent characteristics on an individual’s appraisal of a service/product. Through evaluation of a series of hypothetic scenarios, the relative importance of the different attributes that affect an individual’s choice is elicited. Unlike a direct rating of the importance of each attribute in isolation, conjoint analysis forces trade-offs in the importance of the different attributes. Although the conjoint methodology approach to preference elicitation in cancer screening has been used increasingly by decision-making researchers, it has not been employed to study LCS preferences.

The objectives of this research were to: (a) better understand how individuals who are at higher risk of lung cancer view and value the different characteristics of LCS procedures; (b) evaluate the overall propensity for LCS adoption; and (c) explore individual characteristics that correlate with attribute preferences and overall screening propensity.

MATERIALS AND METHODS

2.1 Overview

This study was approved by the University of Miami and University of Kentucky Institutional Review Boards. We conducted an online survey of a nationally representative sample (n = 210) of individuals at increased risk for lung cancer. The survey collected information on respondent demographic characteristics, and included a conjoint exercise to assess respondents’ attitudes toward different aspects of LCS. Respondents were identified and the survey administered using an internet-based survey panel, KnowledgePanel® (now GfK Knowledge Networks; http://www.knowledgenetworks.com/GANP/).

2.2 Respondents

Knowledge NetworksTM (KN) conducted online surveys using the web-enabled KnowledgePanel®, a probability-based panel designed to be representative of the United States population. To establish and maintain its panel, KN conducted random digit dialing. Persons in selected households were invited to participate in the panel and provided with an internet appliance and connection, if needed.

The target population included English-speaking individuals 45 years of age or older who were former or current smokers with at least a 20 pack-year history and had no history of lung cancer. This sample was selected as representing individuals who are at higher risk for lung cancer, and who maybe be in a position to consider screening (even if they do not meet current criteria). Additionally, we targeted a sample that was approximately 50% female; 25% African American and 25% Hispanic; and 25% rural dwelling. The target sample size of n = 200 was based on a conservative approach to the sample size estimation algorithm for conjoint methodology. The available background information on KN Panel members included smoking history and current smoking status, but not enough information to calculate pack-years smoked. Therefore, initial eligibility questions for KN panel participants were needed to establish individuals’ overall tobacco exposure. Of the 525 individuals invited to participate, 223 met eligibility criteria including smoking history, and 210 individuals completed the online survey (94%).

2.3 Survey development

The survey included standard demographic and smoking related items drawn from previous federal surveys. However, the CVA instrument was newly developed as part of this study. Conjoint methodologies were originally developed in psychology and most broadly employed by marketing researchers. More recently, conjoint methods have been increasingly been used in medical decision-making context to assess the importance of factors that influence decisions about healthcare services.

In developing a conjoint evaluation instrument, we conducted semi-structured interviews with 40 smokers and 9 health-care providers to collect information on LCS characteristics that might be most important and salient regarding individuals’ decisions about screening. Based on these interviews
and team expertise, we identified five attributes of LCS that were likely to be influential in decisions about screening. These attributes, along with the different levels, are listed in Table 1. Aiming for orthogonality and parsimony in our selection of scenarios, we used Sawtooth software (Inc Orem, UT) to identify 20 unique conjoint scenarios. Survey respondents rated each scenario on a 9-point Likert type ratings scale anchored by “would definitely not get screened” and “would definitely get screened.” See Figure 1 for an example scenario.

### 2.4 Online survey procedures

Knowledge Networks™ sent invitations in batches to panel members likely to meet the eligibility criteria. As mentioned above, the KN databases did not include sufficient information to calculate volume of tobacco exposure, so additional assessment of pack-years was necessary to determine eligibility. Each respondent received a $30 honorarium. All data were entered directly into online databases so there were few missing data. Data were only missing if a participant refused to answer questions or terminated the survey before it was completed.

#### 2.5 Data analysis

Data analysis included both descriptive summaries of data and multivariate statistics. All analyses were performed using Stata 13.0 and/or Sawtooth Software. Summary
statistics for all demographic characteristics were calculated first.

Using Sawtooth software, we calculated relative importance scores for attributes and part-worth utilities for each respondent, as well as the mean for the sample population. Relative importance of an attribute in our analyses is a measure of how much influence each characteristic (such as cost or false-positive rate) has on an individual’s willingness to be screened. Relative importance scores for each individual sum to 100. Part-worth utilities reflect the desirability (or lack of undesirability) of a given level of an attribute. We used a hierarchical Bayes approach, which uses averages (information about the distribution of utilities from all respondents) as part of the procedure to estimate attribute level utilities for each individual.

To characterize each respondent’s overall propensity for screening, we calculated the average of their ratings (scale of 1-9) for the 22 conjoint scenarios.

Finally, we used univariate regression analyses to examine associations between demographic characteristics (all characteristic in Table 2) and (a) the relative importance ratings for each attribute and (b) the average propensity to screen. We used a Bonferroni correction to ameliorate the chance of Type 1 errors due to multiple comparisons.

3 | RESULTS

3.1 | Characteristics of study respondents

Mean age of respondents was 61 years (SD 8.5), and 51.9% of respondents were female (Table 2). Average pack-years of smoking was 40 (SD 20.1), with early onset of both first smoking (16 years, SD 2.9) and regular smoking (18 years, SD 5.3). Less than half of respondents were current smokers (40.6%) and, of those, 74.7% had tried quitting. The majority was married or cohabitating (66.2%). Consistent with our desired sampling frame, respondents were 46.4% White, non-Hispanic; 25.2% Black, non-Hispanic; and 28.5% Hispanic. Respondents were relatively evenly distributed across income groups, and most had a high school education or some college (70.5%). About half of respondents had medical insurance through an employer. Of the 210 participants, 74.6% reported being in “good” to “excellent” health.

3.2 | Relative importance of the attributes of the lung cancer screening scenarios

As described, the relative importance of an attribute is a measure of how much influence each attribute has on respondent choices. The average relative importance of the five attributes varied from a high of 27.3 (SD 17.7) for out of pocket costs to a low of 14.8 (SD 7.3) for ease of access (Figure 2), indicating that cost is likely to play a highly influential role in screening implementation. However, all of the attributes appeared to influence choices, including provider recommendation (24.8, SD 13.4), mortality reduction (17.2, SD 8.9), and false-positive rate (15.8, SD 10.4).

Variation in individuals’ relative importance scores and propensity for screening was quite large (Figure 2). Individual importance scores ranged from the single digits (for all five attributes) to over 50 (for health-care provider recommendation – max of 64% and out of pocket cost – max of 87%). Similarly, average propensity to be screened also varied widely from 1 to 9.

3.3 | Part-worth utilities for attribute levels

Part-worth utilities measure the “desirability” of each level of an attribute relative to the other levels of that attribute. For example, the attribute of false-positive rate has
part-worth utility scores of: 21.1 for a 10% false-positive rate, 2.6 for a 25% false-positive rate, and −23.7 for a 40% false-positive rate (Figure 3). This indicates that respondents find a 10% false-positive rate much more desirable than a 40% false-positive rate. The part-worth utility values for levels in a given attribute are zero-centered, and sum to zero.

Patterns within the part-worth utility values for the levels of out of pocket cost, mortality reduction, and false-positive rate are consistent with the natural ordering, as expected. $50 out of pocket costs was preferred to $500 (68.8 vs −54.2), 20% mortality reduction was preferred to 1% (17.6 vs −31.1), and 10% false-positive rate was preferred to 40% (21.1 vs −23.7). In addition, a health-care provider recommendation against LCS had the lowest part-worth utility (−35.8) for that attribute, indicating that screening was least desirable when a provider recommended against it. In terms of access, respondents found the LCS conditions with extended hours most desirable.

3.4 Propensity to be screened
The average propensity for screening, on a scale of 1-9, was just 3.63 (SD 1.6), indicating relatively low inclination for screening. Among the 22 hypothetical scenarios, the average ratings ranged from 2.60 (SD 2.00) to 5.57 (SD 2.13). The most favorable screening scenario's attributes were: $100 out of pocket costs; 10% reduction in mortality; PCP recommendation to screen; 10% false-positive rate and inconvenient location but open evenings and weekends. Even with these characteristics, the average willingness to be screened was only slightly over the midpoint from "definitely no" to "definitely yes". (NB: Since not all combinations of attribute levels were used for conjoint scenarios, our "best" scenario in the survey was not the "best possible" scenario.)

3.5 Univariate associations
After planned Bonferroni adjustment for multiple comparisons, the only significant associations of important scores/propensity to be screened with respondent demographic characteristics were: (a) a negative association between income and the importance of cost for screening decisions ($P < 0.05$), and (b) a positive association between race/ethnicity of Black non-Hispanic and higher average propensity to be screened ($P < 0.05$).

4 DISCUSSION
Low-dose CT screening has been shown to reduce lung cancer mortality in selected high-risk groups and is covered by both Medicare and a large number of private insurance companies. However, screening is not without risks and constitutes a quintessential “preference-sensitive” decision. Therefore, it is important that informed decision making for LCS be emphasized, and as part of that, understanding the factors that affect higher risk individuals’ attitudes toward screening and screening decisions provides key information on how to engage candidates. This research provides unique information on attributes of LCS and the influence these aspects likely have on decisions to pursue screening.

Results show the relative importance values that potential screening candidates place on 5 screening attributes previously identified as potentially influential through qualitative research (see Table 1). Specifically, decisions about screening were most highly influenced by cost, with health-care provider recommendations a close second. Surprisingly, reduction in mortality and false-positive rates associated with screening was not nearly as influential on decisions at a
population level. However, we also found a wide variation in which factors/attributes were most influential.

Similar to other cancer screening contexts, we found that clinician recommendations played a substantial role in patient ratings of anticipated screening [eg, 35], highlighting the importance of clinician-patient communication and training with regard to LCS and shared decision making. However, some previous studies of primary care clinicians36-39 have demonstrated suboptimal knowledge, attitudes, and practices with regard to LCS. For example, only 22%36 to 31%39 of primary care providers knew the correct LCS eligibility criteria, which led to inappropriate LCS referrals. Thus, our research highlights the need for up-to-date knowledge about LCS among primary care providers.

Previous research on LCS has shown relatively favorable attitudes toward screening when participants are asked about interest in screening or willingness to be screened [eg, 19-22]. However, conjoint-generated "propensity" to be screened results show generally low levels of interest in screening when the respondent is considering a more fully described screening scenario. These findings are in alignment with LDCT screening uptake data, specifically that the actual number of people being screened for lung cancer following publication of the NLST is lower than anticipated.40,41

Achieving optimal implementation of LCS (including individual preferences as well as objective risk factors) requires development of comprehensive and organized LCS programs and rigorously quality standards. To date, this has not occurred on a national level (only individual programs). Part of the reason for this may be the relative recency of recommendations for LCS by USPSTF and other organizations. However, other barriers to achieve optimal screening—which may be even more difficult to overcome include achieving suitable availability and access to high-quality screening programs, and improving patient navigation across the screening cascade.

Limitations of this study are consistent with other studies that elicit preferences and explore decision making using conjoint methods. First, attribute preferences and intention to screen in a hypothetical scenario are treated as an indication of real-world attribute preferences and actual screening behavior, despite their differences.42 Second, the attribute information is, by necessity, presented in a simplified way which may lead to biases in judgement. Finally, despite a degree of oversimplified attribute information, conjoint analyses can be complex for participants. However, we restricted our conjoint scenarios to a number previously shown not to induce decision fatigue,43 and the order of scenario presentation was randomized to reduce potential order effects.

Our study also has several important strengthen. Our sample population was nationally representative with additional oversampling by race/ethnicity. Our conjoint scenarios were developed using a rigorous mixed methods approach. Use of the conjoint methodology allowed us to capture a variety of benefits, harms and other potentially important factors in LCS decisions. Finally, qualitative feedback indicated great potential for the future use of conjoint exercises as part of an informed and shared decision making process for LCS.

5 | CONCLUSIONS

Overall, findings highlight the need for patients to be educated about both the benefits (eg, mortality reduction) and risks (eg, false-positive rates) of LCS. Information on these and other aspects of screening has to be presented in a way that is comprehensible and relevant. In addition, if we want to help individual patients make the most appropriate decision about screening for themselves, eliciting preferences and putting data in the context of the screening candidate must be a
vital component of that process. Only in this way will we be able to ensure quality decision making for LCS.

ACKNOWLEDGMENTS

We thank the National Cancer Institute for supporting this research.

CONFLICT OF INTEREST

No authors have any conflicts of interest to report.

AUTHOR CONTRIBUTIONS

All listed authors meet the four criteria definition of authorship: (a) Substantial contribution to the conception, design, analysis, or interpretation; (b) Contributed to drafting or revising the manuscript; (c) Provided final approval of the submitted version; and (d) Agree to be accountable for all aspects of the work.

MMB had full access to all of the data in the study and takes responsibility for the integrity of the data analysis, including and especially any adverse effects. MMB, RJT, and JLS contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript.

ORCID

Margaret M. Byrne https://orcid.org/0000-0002-8143-4702

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2019;69(1):7-34.
2. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
3. Moyer VA, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-338.
4. American Lung Association. American Lung Association Provides Guidance on Lung Cancer Screening. http://www.lung.org/lung-disease/lung-cancer/lung-cancer-screening-guidelines/.
5. The Centers for Medicare & Medicaid Services. Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N). http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274.
6. Deterreck FC, Mazzzone PJ, Naidich DP, Bach PB. Screening for lung cancer: diagnosis and management of lung cancer, 3rd edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e78S-e92S.
7. Jaklitsch MT, Jacobson FL, Austin J, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012;144(1):33-38.
8. National Comprehensive Cancer Network. Lung Cancer Screening. http://www.nccn.org/professionals/physician_gls/l_ guidelines.asp.
9. Wender R, Fontham E, Barrera E, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63(2):106-117.
10. De Koning H, Van Der Aalst C, Ten Haff K, et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomized-controlled population based trial. 2018. World Conference on Lung Cancer. http://library.iaslc.org/conference-program?product_id=10; Presented September 25, 2018.
11. Sheridan SL, Harris RP, Woolf SH; Shared Decision-Making Workgroup of the U.S. Preventive Services Task Force. Shared decision making about screening and chemoprevention. A suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. 2004;26(1):56-66.
12. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418-2429.
13. Patz EF, Pinsky P, Gatsonis C, et al. NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269-274.
14. Veronesi G, Maisonneuve P, Bellomi M, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2012;157(11):776-784.
15. De Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of lung cancer screening: modeling strategies for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):311-320.
16. Slatore CG, Sullivan DR, Pappas M, Humphrey LL. Patient-centered outcomes among lung cancer screening recipients with computed tomography: a systematic review. J Thorac Oncol. 2014;9(7):927-934.
17. Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer and perceived risk of cancer following lung cancer screening. Med Dec Making. 2008;28(6):917-925.
18. Harris RP, Sheridan SL, Lewis CL, et al. The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA Intern Med. 2014;174(2):281-285.
19. Lillie SE, Fu SS, Fabbri AE, et al. What factors do patients consider most important in making lung cancer screening decisions? Findings from a demonstration project conducted in the Veterans Health Administration. Lung Cancer. 2017;104:38-44.
20. Delmerico J, Hyland A, Celestino P, Reid M, Cummings KM. Patient willingness and barriers to receiving a CT scan for lung cancer screening. Lung Cancer. 2014;84(3):307-309.
21. Jonnalagadda S, Bergamo C, Lin JJ, et al. Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer. 2012;77(3):526-531.
22. Tanner NT, Egede LE, Shamblin C, Gebregziabher M, Silvestri GA. Attitudes and beliefs toward lung cancer screening among US Veterans. Chest. 2013;144(6):1783-1787.
23. van der Pol M, Ryan M. Using conjoint analysis to establish consumer preferences for fruit and vegetables. British Food J. 1996;98(8):5-12.
24. Brenner A, Howard K, Lewis C, et al. Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia. J Gen Intern Med. 2014;29(3):507-513.

25. Bridges J, Kinter ET, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982-2007. The Patient. 2008;1(4):273-282.

26. Pignone MP, Brenner AT, Hawley S, et al. Conjoint analysis versus rating and ranking for values elicitation and clarification in colorectal cancer screening. J Gen Intern Med. 2012;27(1):45-50.

27. Pignone MP, Howard K, Brenner AT, et al. Comparing 3 techniques for eliciting patient values for decision making about prostate-specific antigen screening: a randomized controlled trial. JAMA Intern Med. 2013;173(5):362-368.

28. Tsunematsu M, Kawasaki H, Masuoka Y, Kakehashi M. Factors affecting breast cancer screening behavior in Japan—assessment using the health belief model and conjoint analysis. Asian Pac J Cancer Prev. 2013;14(10):6041-6048.

29. Knowledge Networks [Internet]. http://www.knowledgenetworks.com/ganp/.

30. Orme BK. Sample size issues for conjoint analysis studies. Sawtooth Software Research Paper Series, Sawtooth Software, Inc; 1998.

31. Bridges J, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403-413.

32. Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3-13.

33. Mansfield C, Tangka FK, Ekwueme DU, et al. Stated Preference for cancer screening: A systematic review of the literature, 1990-2013. Prev Chronic Dis. 2016;13:E27.

34. Allenby GM, Rossi PE, McCulloch RE (January 2005). Hierarchical Bayes Model: A Practitioner’s Guide. White paper 2005: Accessed January 31, 2019. http://faculty.washington.edu/bajari/iosp07/rossi1.pdf.

35. Peterson EB, Ostroff JS, DuHamel KN, et al. Impact of provider-patient communication on cancer screening adherence: a systematic review. Prev Med. 2016;93:96-105.

36. Khairy M, Duong DK, Shariff-Marco S, et al. An analysis of lung cancer screening beliefs and practice patterns for community providers compared to academic providers. Cancer Control. 2018;25:1-8.

37. Triplette M, Kross EK, Mann BA, et al. An assessment of primary care and pulmonary provider perspectives on lung cancer screening. Ann Am Thorac Soc. 2018;15(1):69-75.

38. Simmons VN, Gray JE, Schabath MB, Wilson LE, Quinn GP. High-risk community and primary care providers knowledge about and barriers to low-dose computed tomography lung cancer screening. Lung Cancer. 2017;106:42-49.

39. Duong DK, Shariff-Marco S, Cheng I, et al. Patient and primary care provider attitudes and adherence towards lung cancer screening at an academic medical center. Prev Med. 2017;66:17-22.

40. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States-2010 to 2015. JAMA Oncol. 2017;3(9):1278-1281.

41. Huo J, Shen C, Volk RJ, Shih YT. Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: Intended and unintended uptake. JAMA Intern Med. 2017;177(3):439-441.

42. Power E, van Jaarsveld CH, McCaffery K, Miles A, Atkin W, Wardle J. Understanding intentions and action in colorectal cancer screening. Ann Behav Med. 2008;35(3):285-294.

43. Johnson RM, Orme BK. How many questions should you ask in choice-based conjoint studies? Sawtooth Software Research Paper Series: Sawtooth Software, Inc; 1996.

How to cite this article: Byrne MM, Thurer RJ, Studts JL. Individual decision making about lung cancer screening: A conjoint analysis of perspectives among a high-risk national sample. Cancer Med. 2019;8:5779–5786. https://doi.org/10.1002/cam4.2445